Urology Times 50 Innovations Series: Dr. Kelvin Moses on sipuleucel-T for mCRPC

Video

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are high-lighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Kelvin A. Moses, MD, PhD, discusses the prostate cancer treatment sipuleucel-T (Provenge). Moses is an associate professor of urology and fellowship director of urologic oncology at Vanderbilt University Medical Center, Nashville, Tennessee.

Related Videos
Roger R. Dmochowski, MD, MMHC, FACS, answers a question during a Zoom video interview
Charles Parker, MD, answers a question during a Zoom video interview
Doctor holding patient's hands | Image Credit: © bongkarn - stock.adobe.com
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
Roger R. Dmochowski, MD, MMHC, FACS, answers a question during a Zoom video interview
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Dr Daniel Allen Hamstra
Related Content
© 2023 MJH Life Sciences

All rights reserved.